MAPK3 and glioblastoma: Since EGFR is a key regulator in glioblastoma growth and upstream of both the MAPK and PI3K/AKT pathways, inhibitors targeting EGFR and ERK1/2 were selected to assess their interactions with LSD1 inhibition.